Drug Trial Radar · NCT07025811
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
378
Actual
Start
Jul 9, 2025
Primary completion
Jul 16, 2026
Study completion Jul 16, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the performance of biomarkers and their responsiveness to standard-of-care treatments (Vevye® or Xiidra®), in participants with dry eye disease (DED) compared to healthy volunteers (control participants).
Conditions
- Dry Eye Disease
Interventions
Vevye®Drug
Participants will receive Vevye® (0.1% cyclosporine ophthalmic solution) as per the schedule described in the treatment arm.
Xiidra®Drug
Participants will receive Xiidra® (5% lifitegrast ophthalmic solution) as per the schedule described in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Corneal Staining as Measured by Sodium FluoresceinTime frame: Up to Week 12
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Eye Research Foundation
Newport Beach, California
Butchertown Clinical Trials
Louisville, Kentucky
Andover Eye Associates
Andover, Massachusetts
Oculus Research
Garner, North Carolina
CORE Inc.
Shelby, North Carolina
Advancing Vision Research, LLC
Goodlettsville, Tennessee
Total Eyecare, P.A.
Memphis, Tennessee
Piedmont Eye Center
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.